SecBot SecBot
Biotech Drug Report Generated Nov 7, 2026

ZEVTERA

INVA·Innoviva, Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and commercially available in the US since May 2025.
Why 4/10
ZEVTERA is already FDA-approved (April 2024) and commercially available (May 2025) with no pending PDUFA, pivotal readout, or regulatory decision in the next 12 months. The next catalysts are commercial execution metrics (quarterly sales, formulary wins), which are not hard binary events. Per the impact score rubric, an approved drug with no pending regulatory decision scores 3-5.
Actionable Insight NEUTRAL

ZEVTERA is already approved and commercially available, so the next catalysts are quarterly sales figures and formulary adoption updates. Watch Innoviva's Q4 2026 earnings (expected early February 2027) for ZEVTERA's contribution to the IST product sales trajectory and whether the company raises its 2027 guidance. The stock trades near its 52-week low (~$19) with a mean analyst price target of $35, implying the market may be discounting the commercial ramp.

Price Chart

Loading chart...

Executive Summary

ZEVTERA (ceftobiprole medocaril) is an advanced-generation cephalosporin antibiotic approved by the FDA in April 2024 for three indications: Staphylococcus aureus bloodstream infections (including MRSA-caused right-sided endocarditis), acute bacterial skin infections, and community-acquired pneumonia. Innoviva (NASDAQ: INVA) acquired exclusive US marketing rights from Basilea Pharmaceutica in December 2024 for up to $227 million and launched the drug in May 2025. It is the first and only FDA-approved cephalosporin for MRSA bloodstream infections and holds 10 years of US market exclusivity. Innoviva's Specialty Therapeutics segment, which includes ZEVTERA alongside XACDURO, GIAPREZA, and other products, generated $43.3 million in US net product sales in Q3 2026 (45% year-over-year growth). The company is on track to achieve at least $150 million in full-year 2026 product sales. With no upcoming regulatory catalysts, ZEVTERA's investment thesis hinges on commercial execution and formulary adoption.

How It Works

ZEVTERA is an injectable antibiotic (a cephalosporin) that kills bacteria by blocking cell wall formation. It is classified as an advanced-generation cephalosporin, meaning it has a broader spectrum of activity than older versions. Crucially, it works against methicillin-resistant Staphylococcus aureus (MRSA), a dangerous 'superbug' that resists many common antibiotics. It is given intravenously in a hospital setting.

Trial Status

ZEVTERA was approved by the FDA on April 3, 2024, based on Phase 3 trials including the ERADICATE study (SAB, non-inferiority vs daptomycin) and studies in ABSSSI and CABP. Post-approval surveillance data presented at IDWeek 2026 confirmed sustained activity against MRSA. The drug is now commercially available in the US through Innoviva's Specialty Therapeutics subsidiary.

The Two-Sided Case

▲ Bull Case5
ZEVTERA is the first and only FDA-approved cephalosporin for Staphylococcus aureus bacteremia (SAB) including MRSA-caused right-sided endocarditis, addressing a significant unmet medical need with no direct cephalosporin competitor.
Innoviva's IST segment delivered $43.3M in US net product sales in Q3 2026 (45% YoY growth), and the company is on track for at least $150M in full-year 2026 product sales, with ZEVTERA as a key growth driver.
The drug has 10 years of US market exclusivity and was designated a finalist for the 2026 Prix Galien USA Best Pharmaceutical Product Award, reflecting clinical differentiation.
Analyst consensus is bullish: 9 of 11 analysts rate the stock Buy or Strong Buy, with a mean price target of ~$35 (roughly 83% upside from the ~$19.10 close), and the company is actively repurchasing shares under a $125M buyback program.
Post-approval surveillance data presented at IDWeek 2026 confirmed ceftobiprole retains activity against nearly all MRSA isolates, supporting its clinical utility.
▼ Bear Case4
ZEVTERA faces entrenched competition from established MRSA antibiotics like daptomycin (Cubicin) and vancomycin, which have decades of clinical experience and formulary positioning.
Innoviva's Q3 2026 net loss of $73.9M (driven by $139.5M in unfavorable investment fair-value changes) and total revenue decline of 1.6% YoY raise questions about the company's overall financial trajectory despite product sales growth.
Several large institutional holders (Arrowstreet Capital, Man Group, JPMorgan) significantly trimmed or exited INVA positions in Q2 2026, signaling mixed institutional conviction.
Peak sales estimates for ZEVTERA vary widely ($300M-$500M) and the drug's hospital-focused sales model means adoption may be gradual as formularies update.

Upcoming Catalysts

  • Q4 2026 earnings (expected early February 2027): ZEVTERA sales contribution and 2027 product sales guidance
  • Formulary adoption updates at major US hospital systems
  • Potential expansion of label or pediatric data readouts

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Innoviva, Inc. 8-K INVA ·Originating report

Sources · 10

Hover a chip for the title
1 fda.gov2 businesswire.com3 biospace.com4 nasdaq.com5 edisongroup.com6 contagionlive.com7 innovivaspecialtytherapeutics.com8 drugs.com9 basilea.com10 tradingview.com